US 11,833,153 B2
N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
Simona Bindi, Milan (IT); Davide Carenzi, Travedona Monate (IT); Ilaria Motto, Nerviano (IT); and Maurizio Pulici, Caponago (IT)
Assigned to Nerviano Medical Sciences S.R.L., Nerviano (IT)
Filed by Nerviano Medical Sciences S.R.L., Nerviano (IT)
Filed on Sep. 29, 2022, as Appl. No. 17/936,576.
Application 17/140,471 is a division of application No. 16/721,267, filed on Dec. 19, 2019, granted, now 10,918,642, issued on Feb. 16, 2021.
Application 16/721,267 is a division of application No. 16/312,061, granted, now 10,561,660, issued on Feb. 18, 2020, previously published as PCT/EP2017/064904, filed on Jun. 19, 2017.
Application 17/936,576 is a continuation of application No. 17/140,471, filed on Jan. 4, 2021, granted, now 11,491,158.
Claims priority of application No. 16175386 (EP), filed on Jun. 21, 2016.
Prior Publication US 2023/0107393 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01); C07D 513/04 (2006.01); A61P 37/00 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61K 31/4355 (2006.01); A61K 31/4365 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/4355 (2013.01); A61K 31/4365 (2013.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] 3 Claims
 
1. A combined preparation for simultaneous, separate or sequential use in anticancer therapy, said combined preparation comprising a compound of formula (I)

OG Complex Work Unit Chemistry
wherein
n is 0, 1 or 2;
R1 is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl;
R2 and R3 are independently halogen, cyano, OR4 or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl, wherein
R4 is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl;
E1 and E2 are independently CH or N;
A is O, S or NRS, wherein
R5 is hydrogen or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl;
or a pharmaceutically acceptable salt thereof, and
one or more chemotherapeutic agents.